Mirocals – Still no transparency
It is now January 8th 2024 with no further update from the MND Association and the Mirocals Consortium regarding the only realistic viable new treatment candidate for our community in the next 2 years, and that is low-dose Interleukin 2.
About 2000 patients in the UK have lost their lives since the exciting top line data for the Mirocals trial was announced in 2022.
We call on the MND Association and the Mirocals Consortium to make a clear and transparent statement. If the trial has failed, those living with MND, their families and friends will bite the bullet and move on.
But the ongoing delay of the results of a trial involving 200+ patients is now simply too long.
Our community deserves full transparency now on the causes of the delay, whether scientific, commercial or both. Transparency should be a prerequisite for a trial funded by taxpayers and charity donors. Please give us this clarity now.
We also seek clarity on why both MND Association, and the Consortium, have consistently referenced a new drug, ILT-101, to be developed by the small bio-tech company ILTOO, since the sale of exclusive rights to the trial data to it in April last year. Low-dose Interleukin 2 is already easily compounded from the commercial grade product, Proleukin™️(as used in the trial) and is readily available now in NHS Pharmacies.
Is this because you believe ILT-101 will be available sooner in sufficient quantities in the UK than the trial drug? Or because MND Association and the Consortium are contractually tied to ILTOO and ILT-101?
Again, the community, taxpayers and charity donors deserve to know.
We are United2EndMND - Changing the conversation 